IMR Press / FBL / Volume 13 / Issue 13 / DOI: 10.2741/3052

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Arterial remodeling in vascular disease: a key role for hyaluronan and versican
Show Less
1 Hope Heart Program, Benaroya Research Institute at Virginia Mason, 1201 9th Avenue, Seattle, WA

*Author to whom correspondence should be addressed.

Academic Editor: Mark Slevin

Front. Biosci. (Landmark Ed) 2008, 13(13), 4933–4937; https://doi.org/10.2741/3052
Published: 1 May 2008
Abstract

Hyaluronan and versican are extracellular matrix (ECM) macromolecules that are present in low amounts in normal blood vessels, but increase dramatically in vascular disease. These ECM components are particularly enriched in intimal hyperplasia as seen in human restenotic lesions following balloon angioplasty and provide a permissive environment for arterial smooth muscle cell (ASMC) proliferation, migration, and macrophage adhesion. Interference with the association of hyaluronan and versican with the surface of ASMCs, either through short oliogosaccharides of hyaluronan or blocking antibodies to the hyaluronan receptor, CD44, blocks the proliferative and migratory response of these cells to growth factors, such as platelet derived growth factor (PDGF). Agents that interfere with the proliferative response of ASMCs and that are used in the treatment of restenosis, such as rapamycin, inhibit the synthesis of hyaluronan by these cells. Inhibition of versican by versican antisense blocks proliferation of SMCs. The synthesis of hyaluronan and versican is highly regulated and influenced by pro-inflammatory growth factors such as PDGF and transforming growth factor-beta (TGF-beta).

Share
Back to top